相关内容
下载与本次活动及主题相关的内容。
Biopharma APAC Confex is Asia-Pacific’s most comprehensive decision-maker-only biopharma conference and exhibition, bringing together 2,000+ attendees and 700+ companies across six co-located specialist conferences.
Biopharma APAC Confex is Asia-Pacific’s most comprehensive decision-maker-only biopharma conference and exhibition, bringing together 2,000+ attendees and 700+ companies across six co-located specialist conferences.
Covering multiple biopharma modalities and critical functions across the drug development and manufacturing value chain, the Confex brings together communities spanning biologics manufacturing, clinical development, ADCs, cell & gene therapy, oligonucleotides & peptides, and biopharma supply chain.
What makes Biopharma APAC Confex different is both the breadth of the ecosystem it covers and the quality of the audience it brings together. Every biopharma attendee is a decision-maker, creating a highly focused environment for knowledge exchange, technology discovery, meaningful conversations and strategic partnerships.
Through six specialist conferences, a focused exhibition, partnering, curated networking, awards and social experiences, Biopharma APAC Confex connects biopharma leaders with technology innovators, CDMOs and solution providers from across Asia-Pacific.
Six specialist conferences. Multiple biopharma modalities. 100% decision-makers. One connected APAC biopharma ecosystem.


查看核心主题
Biopharma Asia Pacific Conference, Exhibition & Awards 2027
Explore the latest breakthroughs in single-use systems, end-to-end continuous processing, and next-generation biologics manufacturing innovations that will redefine efficiency.
Gain practical insights into upstream and downstream process improvements, from cost reduction to timeline acceleration, to ensure your biologics pipeline stays competitive and robust.
Stay ahead of changing regulations with updates from international regulators and big pharma, ensuring you meet evolving requirements and quality standards across Asian markets.
Discover new opportunities in manufacturing advanced biologics and novel modalities, and learn how to overcome current challenges to unlock the full potential of next-generation therapies.
Connect with Asia’s top biopharma leaders and global experts through a carefully curated networking platform designed to spark strategic partnerships and drive industry collaborations
立即注册以预留您的席位。
我们精选的专家将分享关于这一动态领域最新趋势、挑战和发展的见解。与这些极具影响力的思想领袖共同参与独特的讨论,了解前沿科学发现,并探索生物制药的未来。


Dr. Alap Gandhi, Country Medical Director, GSK Malaysia, brings with himself over 17 years of experience in the healthcare industry having worked with organizations like WHO, GSK and AstraZeneca pharmaceuticals.
Dr. Alap Strongly believes in the purpose to unite science, technology, and talent to get ahead of disease together and positively impact the health of billion people.
His interests include application of the science of medicines and vaccines from early development and throughout the lifecycle to deliver improvement in patient and population health outcomes. Dr. Alap is MBBS, MD and has additional qualifications of eMBA, PDCR and PGCDDR (Kings College, London).


Chang Teck Chung is the Site Quality Head at Takeda Manufacturing Singapore, overseeing quality operations for commercial and clinical biologics drug substance production.
With over 35 years of experience across pharmaceutical, nutrition, petrochemical and biopharmaceutical sectors, he has led Quality, Technical Services, manufacturing, and supply chain functions with MNCs such as Exxon, MSD Singapore greenfield start-up, and GSK. Before Takeda, Teck Chung held regional and site Quality leadership at Abbott and previously led Technical Services and Quality at Pfizer/Wyeth Nutrition Singapore from its 2000 greenfield start-up.
During his tenure at Takeda, Teck Chung undertook a two-and-a-half-year international assignment in Shanghai, where he led the development of the China Quality roadmap and established a dedicated China-for-China corporate Quality function. This initiative supported the Takeda China Business Unit in attaining double-digit annual growth and facilitating 15 NDA product launches over a five-year period.
Teck Chung’s contribution to national workforce development efforts, include being a member on the WSQ Pharmaceuticals Quality (Food Science) Technical Committee under Singapore’s Ministry of Manpower and a SkillsFuture Career Advisor (Manufacturing Sector) with Workforce Singapore.
He holds executive and academic credentials including Leading & Managing Globally from Yale School of Management (USA); an MBA from the University of Tasmania (Australia); a Graduate Diploma in Business Administration from the Singapore Institute of Management; and a Bachelor’s (Honours) in Chemical Engineering from University College Dublin (Ireland).


Santi Purwantini is a senior supply chain professional with extensive experience in planning, scheduling, and operational excellence within complex manufacturing environments. Throughout her career, she has led initiatives that enhance supply chain agility, production reliability, and end-to-end planning performance through data-driven decision-making and digital transformation, achieving 97–99% order fulfillment accuracy.
With a strong background in demand-supply synchronization, inventory optimization, capacity planning, and cross-functional collaboration, Santi has successfully leveraged advanced analytics, automation, and digital technologies to improve operational efficiency and business resilience. Her expertise spans supply planning strategy, risk management, scenario planning, and the implementation of technology-enabled solutions that drive smarter and more responsive supply chains. Her leadership has resulted in a 50% reduction in manufacturing overhead costs and improved supplier on-time delivery performance from 80% to 96% across a network of more than 200 suppliers.
Passionate about Supply Chain 4.0, Santi advocates for the adoption of artificial intelligence (AI), automation, and predictive analytics to build resilient, data-driven supply chains that enhance operational efficiency, strengthen risk management, and deliver sustainable business value. At BioSupply Chain Asia 2027, Santi will present "Smart Supply Chain 4.0: Predictive Logistics, AI, Blockchain & Automation: Driving Enterprise-Wide Digital Transformation Across Manufacturing and Logistics." Her presentation will explore how organizations can harness digital technologies to transform traditional supply chain functions into intelligent, interconnected ecosystems. By integrating AI-driven insights, predictive logistics, blockchain-enabled transparency, and automation, companies can improve forecast accuracy, optimize resources, strengthen resilience, and drive end-to-end operational excellence across manufacturing and logistics networks.
.webp)
.webp)




Professor Waranyoo Phoolcharoen is a leading expert in plant-based biopharmaceuticals, with academic credentials from Chulalongkorn University, Mahidol University, and Arizona State University. Since 2010, she has led pioneering research in molecular pharming at Chulalongkorn University, harnessing plant biotechnology to produce pharmaceutical proteins targeting infectious diseases. In 2018, she co-founded Baiya Phytopharm, a trailblazing company that accelerates drug development using advanced plant-based platforms. This technology significantly reduces production timelines and costs. Committed to innovation and global health, Professor Phoolcharoen’s work continues to transform the field of vaccine and therapeutic protein development in Southeast Asia and beyond


Dr. Qiuming (Miles) Shi is a senior biopharmaceutical executive with 15+ years of integrated experience across R&D, commercial strategy and large-scale technical operations. He has led multiple technology transfers for mRNA vaccines, PCV13, monoclonal antibodies and complex biologics, and has built GMP and WHO PQ–aligned quality systems in emerging markets.
Most recently, Dr. Shi served as Chief Technology Officer at PT Etana Biotechnologies in Southeast Asia, overseeing R&D, Production, Quality, Supply Chain, Digitalization and Engineering. His prior leadership roles at Merck, Sartorius, GE Healthcare and Boehringer Ingelheim span vaccine development, bioprocessing strategy and technical applications across Asia.
Dr. Shi combines deep scientific expertise with operational excellence and multicultural leadership, with a focus on enabling global-scale manufacturing, organisational transformation and sustainable biopharma growth.
.webp)
.webp)
Wonil Kim, Ph.D., is Chief Scientific Officer at Aston Sci, Inc., where he leads the development of mRNA-based vaccines for oncology and infectious diseases using the AI-driven Th-Vac® platform. He earned his Ph.D. in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota and completed postdoctoral fellowships at Harvard Medical School and the NIH. Dr. Kim has served as a Staff Scientist at St. Jude Children's Research Hospital, where he pioneered cancer biology programs, and has held senior R&D positions at GeneOne Life Science and Cyrus Therapeutics. He is recognized for his expertise in mRNA vaccine design and cancer immunology.
.webp)
.webp)
Dr. Xian Zeng, the Co-Founder and CEO of Byterna Therapeutics, leads this enterprising startup at the vanguard of groundbreaking circular mRNA-based immunotherapies.
Holding a PhD in pharmaceutical science from the National University of Singapore, he previously served as Associate Professor at Fudan University School of Pharmacy, spearheading interdisciplinary research in AI-empowered mRNA drug discovery.
Under his visionary leadership, Byterna is pioneering SEAA (Safe, Effective, Accessible, Affordable) in vivo CAR-T therapies for global patients, leveraging proprietary circular mRNA platforms and targeted delivery systems.
请为您的机构选择相应的门票。
*参会门票必须按正确的类别购买。
生物制药类门票仅限受雇于开发、拥有或商业化治疗性药物产品的制药或生物制药公司的专业人士购买,包括拥有涵盖发现、开发、临床或商业化阶段内部药物管线的机构。此类别适用于主营业务为药物产品开发或制造的公司,不适用于提供赋能技术、设备、平台或服务的公司。
服务、解决方案及技术提供商类门票适用于所有向制药和生物制药行业提供服务、平台、技术、设备、咨询、制造服务或商业解决方案的机构。这包括但不限于 CRO、CDMO、技术和设备供应商、顾问、供应商及解决方案提供商,无论其科学或技术重点为何。
重要提示
所有注册信息均会经过审核,以确保分类正确。购买错误的门票不能保证进入活动现场。IMAPAC 保留拒绝入场、重新分类注册信息以及就正确参会所需的差价开具发票的全部酌情权。对于因选择不当类别而购买的错误门票,在任何情况下均不予退款,包括注册者选择不升级门票或不出席活动的情况。
Early Bird Rate : SGD 1,495
Use discount code: EARLYBIRD
(Valid until 3rd October 2026)
Registration Open Rate : SGD 1,695
Use discount code: REGISTRATIONOPEN
(Valid until 5th December 2026)
Standard Rate : SGD 1,895
Use discount code: STANDARD
(Valid until 6th February 2026)
Final Call Rate : SGD 2,095
Applicable to company profiles (headquartered within the APAC region):
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
Early Bird Rate : SGD 1,995
Use discount code: EARLYBIRD
(Valid until 3rd October 2026)
Registration Open Rate : SGD 2,195
Use discount code: REGISTRATIONOPEN
(Valid until 5th December 2026)
Standard Rate : SGD 2,395
Use discount code: STANDARD
(Valid until 6th February 2026)
Final Call Rate : SGD 2,595
Applicable to company profiles (headquartered outside of the APAC region):
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
Early Bird Rate : SGD 4,295
Use discount code: EARLYBIRD
(Valid until 3rd October 2026)
Registration Open Rate : SGD 4,495
Use discount code: REGISTRATIONOPEN
(Valid until 5th December 2026)
Standard Rate : SGD 4,695
Use discount code: STANDARD
(Valid until 6th February 2026)
Final Call Rate : SGD 4,895
Applicable to company profiles:
Job Profiles: Business Development, Marketing, and Sales
联系 IMAPAC,了解我们的赞助流程、费用及更多信息。
访问活动页面以查看更多内容。
下载与本次活动及主题相关的内容。
Biopharma APAC Confex(亚太生物制药会议、展览及颁奖典礼)是一个区域性的生命科学平台,汇集了亚太地区的生物制药企业、合同服务提供商、科技公司、投资者和行业领袖。该活动集会议、展览和颁奖典礼于一体,旨在促进学习、交流、合作与业务发展。
是的。生物制品制造是本次活动的核心支柱,涵盖了上游工艺、下游工艺、制造策略、MSAT、工艺开发、CMC、质量、工程和供应链管理等内容。
传统的生物工艺会议主要关注制造和工艺开发。Biopharma APAC Confex 的内容不仅限于制造,还涵盖了 ADC、细胞与基因治疗、临床试验、TIDES、供应链以及更广泛的商业和合作机会。
选择哪场活动取决于您的关注领域。专注于上游和下游工艺的专业人士可以考虑专门的生物工艺会议。而那些寻求在生物制品制造、ADC、细胞与基因治疗、临床开发、供应链和外包等领域获得更广泛曝光的人士,则可以从参加 Biopharma APAC Confex 中获益。技术提供商通常会选择参加那些将技术内容与展览及社交机会相结合的活动。
是的。本次展览欢迎技术提供商、CDMO、CRO、设备供应商、软件公司、咨询公司、物流提供商以及其他支持生物制药价值链的组织参展。
Biopharma APAC Awards 旨在表彰亚太地区制药、生物技术、制造、临床开发和供应链领域的卓越表现、创新成果、领导力及成就。
是的。赞助商可以使用活动平台和社交工具与参会者建立联系、安排会议,并识别潜在客户、合作伙伴或协作方。会议预约功能可能因所选的赞助方案而异。
是的。参展商和赞助商可以通过活动平台使用潜在客户信息采集功能,从而获取参会者信息,并高效管理活动后的跟进工作。潜在客户信息采集有助于参展商识别潜在客户、追踪展位互动情况并衡量活动投资回报率。
如需了解活动动态(包括日期、地点和议程),请订阅我们的官方社交媒体渠道,以获取实时更新和公告。
我们致力于确保所有参会者的安全与健康。我们将根据当地的卫生准则和法规实施严格的安全措施。具体的安全措施将在活动临近时公布,以确保其符合最新的健康建议。请放心,您的安全是我们的首要任务。
我们欢迎提交演讲申请。如果您有兴趣在活动中发言,请访问我们网站上的相关页面,查看提交指南和截止日期。
本次活动专为以下领域的专业人士设计:
生物制品生产 | 生物工艺与工艺开发 | 细胞与基因治疗
抗体偶联药物 (ADC) 与生物偶联物 | 临床开发与临床运营 | 供应链与物流
质量与法规事务 | CMC 与技术运营 | 数字化转型与人工智能 | 业务发展与战略合作伙伴关系
本次活动涵盖六大核心行业支柱:
其他议题包括人工智能、数字化转型和自动化。
社交互动通过以下方式实现:
这是活动应用程序中的参会者消息与会议平台。本次活动旨在促进生物制药生态系统内富有成效的商业对话。
是的。亚太生物制药大会(Biopharma APAC Confex)提供专属的活动应用程序,旨在帮助参会者、参展商、演讲嘉宾和赞助商在活动前、活动中及活动后获得最佳体验。通过该应用程序,参会者可以查看议程、联系其他参会者、安排会议、接收活动更新,并浏览展览和会议日程。
是的。注册参会者可以使用活动应用程序查找相关参会人员并提前安排会议。这有助于代表、参展商和赞助商规划日程,并最大限度地利用整个活动期间的交流机会。
亚太地区每年举办多场医药和生物技术会议。亚太生物制药大会(Biopharma APAC Confex)的独特之处在于,它将生物制药生产、ADC、细胞与基因治疗、临床试验、寡核苷酸与多肽以及供应链等领域的专业人士汇聚在同一个平台上。
虽然 Bioprocess International 主要专注于生物工艺和生物制药生产,但亚太生物制药大会(Biopharma APAC Confex)采取了更广泛的生态系统方针,将生产、先进疗法、临床开发、外包、供应链和商业化讨论整合在同一场活动中。
亚太生物制药大会(Biopharma APAC Confex)汇集了来自亚太地区的生产运营负责人、MSAT 专业人士、工艺开发专家、CMC 专家、质量团队、供应链负责人以及技术供应商,是生物制药行业极具价值的交流与业务拓展平台。
我们为企业和组织提供赞助及参展机会。
如需注册参加活动,请点击页面上的任意“注册”按钮开始操作。您可以在其中找到详细的注册说明和选项,包括价格和截止日期。
千万不要错过这些独特的社交、演讲和赞助机会。
Scan this QR code using WeChat or WeCom to connect with our team.
JUNMIN PENG
IMAPAC